Novo Nordisk's weight-loss pill reached 3 million prescriptions in the U.S. since its market launch. Subsequently, the company identified an IT security incident involving unauthorized access to a limited number of internal IT systems. These developments occur as the company continues its operational activities across different markets.
The Danish drugmaker plans to submit a regulatory filing soon for the pill version of its weight-loss drug Wegovy to expand its footprint in China.
Read the full storyThe Danish pharmaceutical giant identified unauthorized access to a limited number of internal IT systems and has engaged external experts to investigate.
Surging demand for oral obesity treatments drives Novo Nordisk to record U.S. growth, outpacing injectable alternatives.
Novo Nordisk has launched the oral version of its obesity drug Wegovy in the UAE, marking the medication's first international debut in pill form outside the US.